Takeda acquires PvP Biologics following coeliac disease drug trial
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
List view / Grid view
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
The FDA has accepted an IND application for AG017, a new drug designed to treat the causes of coeliac disease which will soon enter new trials.
14 November 2016 | By Norma McGough, Director of Policy, Research & Campaigns, Coeliac UK
Coeliac UK’s Director of Policy, Research & Campaigns, Norma McGough, welcomes NICE’s new quality standards on coeliac disease, which she believes will bring clarity and improvement to diagnosis screening and better access to long term treatment…
28 October 2016 | By Dolomite Bio
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at…
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Coeliac UK welcomes NICE quality standards but is concerned that many CCG's in England will not reverse blanket bans on gluten-free prescribing...
19 March 2015 | By Victoria White
Actress and TV personality, Caroline Quentin has been announced as the new Patron of Coeliac UK, the national Charity for people with coeliac disease, and will support their campaign to improve diagnosis rates which is launched at the start of Coeliac Awareness Week on 11 May 2015.